Therapies after auto-HCT in 2 cohorts
| Variables . | Total (N = 215), n (%) . | Cohort 1, 2005-2010 (n = 118), n (%) . | Cohort 2, 2011-2016 (n = 97), n (%) . | P . |
|---|---|---|---|---|
| Anthracycline based (evaluable n = 133) | 31 (23) | 17 (28) | 14 (19) | .25* |
| Gemcitabine based (evaluable n = 145) | 53 (37) | 34 (47) | 19 (26) | .008* |
| Bv (evaluable n = 157) | 98 (62) | 39 (55) | 59 (69) | .07* |
| CPIs | 39 (18) | 4 (3) | 35 (36) | <.001* |
| Before allo-HCT | 5 (8.5) | 0 | 5 (14.7) | |
| Clinical trial participation | 71 (46) | 42 (55) | 29 (38) | .02* |
| Data missing | 62 | 42 | 20 | .066*† |
| Allo-HCT performed | 59 (28) | 25 (22) | 34 (35) | .03* |
| Data missing | 5 | 4 | 1 | |
| Type of allo-HCT | .320*† | |||
| MRD | 14 (24) | 6 (24) | 8 (23.5) | |
| MUD | 30 (51) | 15 (60) | 15 (44) | |
| Haploidentical | 8 (13) | 1 (4) | 7 (21) | |
| Cord blood | 7 (12) | 3 (12) | 4 (12) | |
| Clinical outcome with allo-HCT | ||||
| TRM at 100 d after allo-HCT | 5 (8.5) | 3 (12) | 2 (6) | .641*† |
| Complications related to allo-HCT | .343*† | |||
| aGVHD | 15 (25) | 4 (16) | 11 (32) | |
| cGVHD | 7 (12) | 2 (8) | 5 (15) | |
| Infection | 5 (8.5) | 3 (12) | 2 (6) | |
| Variables . | Total (N = 215), n (%) . | Cohort 1, 2005-2010 (n = 118), n (%) . | Cohort 2, 2011-2016 (n = 97), n (%) . | P . |
|---|---|---|---|---|
| Anthracycline based (evaluable n = 133) | 31 (23) | 17 (28) | 14 (19) | .25* |
| Gemcitabine based (evaluable n = 145) | 53 (37) | 34 (47) | 19 (26) | .008* |
| Bv (evaluable n = 157) | 98 (62) | 39 (55) | 59 (69) | .07* |
| CPIs | 39 (18) | 4 (3) | 35 (36) | <.001* |
| Before allo-HCT | 5 (8.5) | 0 | 5 (14.7) | |
| Clinical trial participation | 71 (46) | 42 (55) | 29 (38) | .02* |
| Data missing | 62 | 42 | 20 | .066*† |
| Allo-HCT performed | 59 (28) | 25 (22) | 34 (35) | .03* |
| Data missing | 5 | 4 | 1 | |
| Type of allo-HCT | .320*† | |||
| MRD | 14 (24) | 6 (24) | 8 (23.5) | |
| MUD | 30 (51) | 15 (60) | 15 (44) | |
| Haploidentical | 8 (13) | 1 (4) | 7 (21) | |
| Cord blood | 7 (12) | 3 (12) | 4 (12) | |
| Clinical outcome with allo-HCT | ||||
| TRM at 100 d after allo-HCT | 5 (8.5) | 3 (12) | 2 (6) | .641*† |
| Complications related to allo-HCT | .343*† | |||
| aGVHD | 15 (25) | 4 (16) | 11 (32) | |
| cGVHD | 7 (12) | 2 (8) | 5 (15) | |
| Infection | 5 (8.5) | 3 (12) | 2 (6) | |